- Home
- ATTO vs OLMA Comparison
ATTO vs OLMA Comparison
Compare ATTO & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATTO | OLMA |
|---|---|---|
| Founded | 2023 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 949.3M |
| IPO Year | 2026 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ATTO | OLMA |
|---|---|---|
| Price | $14.12 | $7.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | ★ $42.20 | $36.50 |
| AVG Volume (30 Days) | 416.7K | ★ 1.1M |
| Earning Date | 09-02-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.00 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.94 | $6.48 |
| 52 Week High | $28.00 | $36.26 |
Technical Indicators
Market Signals| Indicator | ATTO | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 31.42 | 29.95 |
| Support Level | N/A | N/A |
| Resistance Level | $18.38 | $11.27 |
| Average True Range (ATR) | 1.18 | 0.41 |
| MACD | -0.23 | -0.06 |
| Stochastic Oscillator | 21.53 | 25.42 |
Price Performance
Historical ComparisonAbout ATTO Attovia Therapeutics Inc. Common Stock
Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.